Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD.

Christoffer SoendergaardJakob Benedict SeidelinCasper SteenholdtOle Haagen Nielsen

Published in: BMJ open gastroenterology (2018)

Patients with IBD failing vedolizumab induction and anti-TNF therapy have persistent IL-6 pathway activity, which could be a potential alternative treatment target. sCD40L, osteocalcin and the IL-6 pathway activity might be predictors for response to vedolizumab.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
rheumatoid arthritis
stem cells
mesenchymal stem cells
bone marrow